Open AccessLong-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease
Author(s) -
Brian Claggett,
John M. Lachin,
Stefan Hantel,
David Fitchett,
Silvio E. Inzucchi,
Hans J. Woerle,
Jyothis T. George,
Bernard Zinman
Publication year - 2018
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.118.033810
Subject(s) - medicine , empagliflozin , disease , life expectancy , diabetes mellitus , type 2 diabetes mellitus , type 2 diabetes , term (time) , benzhydryl compounds , intensive care medicine , endocrinology , population , physics , environmental health , quantum mechanics , chemistry , organic chemistry , bisphenol a , epoxy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom